All posts by imreal

ASSA ABLOY Introduces New Padlock that Out-Performs in All Weather Conditions


The All Weather Padlock is made of solid 303 stainless steel with a weatherproof cap to protect the cylinder.

You don’t name a padlock the ‘All Weather Padlock’ unless it can live up to its name. The AWP Series has passed rigorous performance testing to offer the highest level of weatherproof protection–ideal for perimeter security gates, storage lockers, cargo containers and transportation trailers.

ASSA ABLOY today announced the introduction of Medeco’s All Weather Padlock (AWP Series), a hefty stainless steel addition to Medeco’s line of high security padlocks. The AWP Series is designed for installations requiring reliable, rugged service performance in the most extreme weather conditions.

“You don’t name a padlock the ‘All Weather Padlock’ unless it can live up to its name,” said David Matherly, Medeco product manager, ASSA ABLOY. “The AWP Series has passed rigorous performance testing to offer the highest level of weatherproof protection making it ideal for outdoor perimeter security gates, outdoor storage lockers, cargo containers and transportation trailers.”

Medeco’s All Weather Padlock’s body is made of solid 303 stainless steel and is available with either a stainless steel or boron alloy shackle. The keyway and electrical contacts are kept clean and dry with a weather-sealed cap on the padlock’s base. The AWP Series is not only weatherproof, it is also a high security lock that resists cutting and pulling attacks. Medeco’s mechanical cylinders provide the additional benefit of patented key control, while both the Medeco CLIQ and Medeco XT cylinders add sophisticated audit and control features.

Technical Information:

  • 300 Series, extruded stainless steel body resists physical attack and corrosion
  • 5/16” and 7/16” diameter, stainless steel and boron alloy shackles
  • 1 7/8”, 2 3/8”, 2”, and 2 ½” shackle lengths
  • Padlocks are shipped with a weather protector seal cap attached by a stainless steel cable
  • Key retaining cylinder design
  • O-ring sealed cap, cylinder, and shackles resist grime and water freeze-up at low temperatures


For more information, visit http://www.medeco.com/awp.

About Medeco:

Founded in 1968 and based in Salem, Va., Medeco is a brand associated with ASSA ABLOY High Security Group, Inc., an ASSA ABLOY Group company. Medeco is a market leader in mechanical and electronic locks and locking systems for security, safety, and control. The company’s customer base includes wholesale and retail security providers, original equipment manufacturers, and institutional, commercial, industrial, and residential end-users. Visit http://www.medeco.com for additional information.

About ASSA ABLOY:

The ASSA ABLOY Group is the global leader in access solutions. The Group operates worldwide with 48,500 employees and sales of SEK 84 billion. The Group has leading positions in areas such as efficient door openings, trusted identities and entrance automation. ASSA ABLOY’s innovations enable safe, secure and convenient access to physical and digital places. Every day, we help billions of people experience a more open world. For more information, visit http://www.assaabloy.com.

Share article on social media or email:

Myant to showcase line-up of heart health management apparel and textiles at CES 2020 to democratize access to electrocardiography for people across society


News Image

Scaling access to medical diagnostics will be necessary to improve global health – novel tools and technologies like wearable textiles holds the potential value to democratize healthcare in a way that has never previously been imagined.

Myant Inc., the pioneers in Textile Computing™, will be showcasing a line-up of textile products that enable continuous and ambient heart health management at CES 2020 (January 7-10, Las Vegas), including apparel from the Skiin Connected Health & Wellness line which was honored as a winner in the Health & Wellness category of the CES 2020 Innovation Awards.

While electrocardiography, or the study of the electrical activity of the heart, has long been recognized as a crucial diagnostic modality in the management of overall health, access to cardiac diagnostics has long been restricted within the context of clinical settings, and offered only to those suffering from, or at significant risk of cardiac disease. Factors such as high cost of care and complexity in diagnostic devices have led to an approach towards heart health management that is largely reactive in nature as opposed to truly preventative.

Enabling Access to Heart Health Management for All via Everyday Clothing

Heart disease is still the leading cause of death in the world, and there is no current way to monitor the heart in an ambient, passive, seamless, and reliable manner – essential to preventative care. Myant’s mission is to create that connection to the human body, through everyday products that are already pervasive in our lives and continuously being used, in order to connect everyone, regardless of their age, gender or ability, and throughout all facets of their lives (i.e. sleep, work, play/fitness, etc.).

Leading healthcare experts like Dr. Suraj Kapa, a cardiologist and medical innovation expert from the Mayo Clinic who advises on healthcare strategy for Myant, agree on the potential for textile to transform the way care is delivered and managed. “Scaling access to medical diagnostics will be necessary to improve global health – novel tools and technologies like wearable textiles holds the potential value to democratize healthcare in a way that has never previously been imagined,” noted Dr. Kapa.

Myant has been working to develop textiles that can sense the electrical activity of the heart, and deploying these textiles in different form factors (i.e. clothing, furniture, car seats, etc.). By distributing the data captured by these interfaces through a cloud-based, AI-enabled platform, Myant is ushering in a model for heart health management that is continuous, ambient, preventative, and democratized. This will create continuous access to best-in-class heart health machine learning algorithms, something that is currently confined to leading hospitals and cardiologists.

Myant will be bringing these products to market under its connected brand Skiin. The line-up of apparel can record ECG data from multiple points of the body to obtain different ECG vectors resulting in more accurate and continuous heart monitoring. The Skiin line-up of interfaces to be showcased at CES 2020 includes:

Interface Details

Underwear    

  • 2-lead electrocardiogram (ECG)
  • Includes activity and temperature monitoring, plus more
  • Launching in Q1 2020

Bra    

  • 3-lead ECG recording garment
  • Includes activity and temperature monitoring, plus more
  • Launching in Q1 2020

Undershirt    

  • 3 to 5-Lead ECG shirt with multiplexing capability between electrodes
  • Includes activity and temperature monitoring, plus more
  • Launching in Q2 2020

Polo Shirt    

  • Single-lead ECG recording polo shirt
  • PPG sensor for ECG-PPG cuffless blood pressure measurement
  • Launching in Q4 2020

Baby Onesie    

  • 3 to 5-lead ECG onesie with multiplexing capability between electrodes
  • Includes activity, position and temperature monitoring, plus more
  • Launching in Q4 2020

Pregnancy Band    

  • 12-lead maternal ECG and fetal ECG monitoring abdominal band
  • Lead selection capability from 16 electrodes for optimal fetal ECG recording

12-Lead Holter Monitor    

  • 12-lead medical grade cardiac Holter monitor
  • Utilizing Myant proprietary fully textile dry motion-resistant active electrodes
  • ECG recording with continuous mechanical/electrical electrode contact monitoring
  • Devices are under pre-submission process with the FDA and are not currently for sale under any jurisdiction.

Distributing ECG and Other Biometric Insights via Social Connectedness App, Deepening Connection with Circle of Care to Address the Social Determinants of Health:

Human interaction and social connectedness are fundamental human needs, and an individual’s health and wellbeing are known to be intrinsically connected to these social determinants. While people in the past lived in tighter knit communities and thus were able to stay more connected and better care for each other, our social connections in the modern world are less physically connected and more dispersed. Myant’s mission is to use technology to help alleviate this problem, and connect people to themselves, their communities, AI and the world around them.

In light of this, ECG data and other biometric data gathered by Skiin garments will be distributed via the Skiin app (powered by the Myant Platform) which promotes sharing of information between the user and their Care Circle. The aim of the app experience is to create a continuous, ambient, and more meaningful bond between the user and their caregivers (e.g. loved ones, healthcare professionals, etc.), providing the user with the support they need to achieve better health outcomes. Members of the Care Circle can check-in on the user via the app to understand their physical and emotional state at a glance, providing greater peace of mind. AI on the Myant Platform works with a nudge system build into the app to alert the user and their Care Circle of important changes to the user’s state, suggesting meaningful actions to help improve wellbeing. The end result is the redistribution of care, from isolated episodes in clinical contexts to a continuous, distributed community-based model in which the user, their loved ones, healthcare providers, and AI all work together to promote better outcomes.

Myant at CES 2020

The democratization of heart health management through connected textiles is just one of the many possibilities enabled by the Myant Platform, which provides a continuous, ambient and passive connection between people and their bodies, their communities, and their environments across all aspects of daily life (i.e. home, work, and play). Myant’s presence at CES 2020 was designed to encourage others to envision these possibilities, inspiring the world to challenge the way they see everyday textile and to reimagine the value that these objects can provide. Myant invites you to visit their booth at CES 2020 (Booth #43925, Sands Expo, Health & Wellness) to discover more about a world connected by textiles.

For more information or to schedule a meeting with Myant at CES 2020, please contact:

Brian Fung

Marketing Strategist at Myant

brian.fung@myant.ca, 416-423-7906 x401

Frank Florio

VP, Strategy & Business Development at Myant

frank.florio@myant.ca, 416-423-7906 x421

About Myant Inc.

Myant has created the world’s first platform that continuously and ambiently connects people to their bodies, to each other, and to the world around them. Using connected textiles that can sense and react to the human body and a platform that enables machine learning driven health and performance outcomes, Myant is on a mission to transform human connectedness. With an extensive patent portfolio, key exclusive relationships within the textile computing industry, a multidisciplinary team of researchers, engineers, data scientists, fashion designers and knitting specialists, and over 80,000 ft² of manufacturing capacity, Myant is changing the way people across society connect. Connect with us to find out how we can help you create innovative solutions powered by connected textiles and the Myant Platform. Visit https://www.myant.ca to learn more.

Following A Year of Tremendous Momentum and Growth, LineSlip Solutions Adds Industry Veteran to Executive Team


LineSlip Solutions, the SaaS company at the heart of the commercial insurance industry’s digital transformation, today announces that Lee Stevenson has joined the company as President. In his new role, Lee will drive sales and support the company’s rapid and continued growth. Stevenson joins the company after spending 25 years at Marsh, most recently as a Managing Director and Operations & Technology Leader for the US and Canada.

“Having Lee Stevenson join LineSlip Solutions is a huge win for the company and represents the first time a senior executive has left a commercial insurance broker for an InsurTech company,” says Leo Bernstein, LineSlip’s Founder and CEO. “His deep industry knowledge, relationships and understanding of our customers’ needs is a game changer for LineSlip. I am looking forward to working with him to develop and deploy software solutions that help brokers, carriers and insureds save time and money by automating manual processes and leveraging the data that is collected during the risk marketing process.”

Lee joins LineSlip Solutions following a year of incredible growth for the New York-based SaaS company. Revenue has grown over 300% year over year and several of the world’s largest commercial insurance brokers and insureds are using the LineSlip Platform. And, 2020 promises to be another year of growth as LineSlip introduces Insights, a game-changing platform for brokers, risk managers and insurance carriers. LineSlip Insight is a SaaS solution that allows brokers and insureds to easily access a consolidated view of their insurance data in order to analyze trends and make smarter business decisions. The solution was met with tremendous excitement at December’s RIMS Risktech Forum.

“There is a growing sense of urgency for digital transformation in the commercial insurance industry,” said Stevenson. “I look forward to helping our customers benefit from the power of modern SaaS for automation and data insights.”

ABOUT LINESLIP SOLUTIONS:

LineSlip Solutions was founded in 2016 by entrepreneurs with over 40 years of commercial insurance experience as brokers, producers, underwriters and executives. Purpose-built for the commercial insurance industry, we have created a framework that uses Natural Language Processing to automatically extract and structure data previously locked in quotes, proposals and other insurance documents. Using that framework, LineSlip Markets allows brokers to easily generate proposals and present quote comparisons while collecting, analyzing and using the data generated in the marketing process to make smarter, more timely business decisions that affect the bottom line. LineSlip Solutions is based in New York City and is actively working with some of the leading brokerage firms in the country.

Share article on social media or email:

MemoryCare.com Names the Best Facilities for Senior Memory Care in Huntsville, AL


News Image

MemoryCare.com, a comprehensive resource for caregivers and older adults living with memory impairment, has announced the Best Memory Care Facilities in Huntsville, Alabama. The guide identifies 5 memory care communities based on location, access to experts, facility features and amenities.

According to the Alzheimer’s Association, 5.6 million people age 65 and older are living with Alzheimer’s dementia. In Huntsville, the number of senior deaths related to Alzheimer’s increased by 30 percent between 2013 and 2017. Memory care facilities offer activities and therapies to help delay or halt cognitive decline. They also give family members and caregivers peace of mind by providing a safe environment for loved ones.

“There’s a high demand for quality memory care all across our nation; specifically, in cities like Huntsville, which experienced a rapid increase in Alzheimer’s related deaths,” says Joyce Collins. “MemoryCare.com provides free resources to help families find the best facilities.”

Through hours of research and an intensive selection process, MemoryCare.com was designed to help caregivers find effective solutions for their loved ones. The website not only highlights the best facilities in the city, it also shares information about cost, reviews from residents, type of care offered and more. For a detailed listing of the Best Memory Care Facilities in Huntsville, AL, please visit https://www.memorycare.com/huntsville-al-facilities/

2020 Best Memory Care Facilities in Huntsville, AL (in alphabetical order)

Brookdale Hampton Cove

Phone: (256) 248-9939

Address: 6379 Highway 431 S., Hampton Cove, AL 35763

Web: brookdale.com/hampton-cover

HarborChase of Huntsville

Phone: (256) 937-1018

Address: 4801 Whitesport Cir. SW., Huntsville, AL 35801

Web: harborchase.com/huntsville

Redstone Village

Phone: (800) 724-5535

Address: 12000 Turnmeyer Dr., Huntsville, AL 35803

Web: redstonevillage.org

Regency Retirement Village of Huntsville

Phone: (256) 852-0033

Address: 2004 Max Luther Dr., Huntsville, AL 35810

Web: regencyhuntsville.com

Thrive at Jones Farm

Phone: (256) 429-3008

Address: 2238 Cecil Ashburn Dr. SE, Huntsville, AL 38502

Web: thrivesl.com/jonesfarm

ABOUT MEMORYCARE.COM

MemoryCare.com provides tools and resources to help adults living with memory impairment and their families. The online guide uses data-driven research and expert evaluations to identify the best facilities across the nation. The MemoryCare.com team includes medical and elder care professionals as well as board of directors. For more information, visit https://www.memorycare.com/.

Share article on social media or email:

The NPD Group Presents Fourth Annual Consumer Electronics Industry Performance Awards at CES 2020


NPD 2020 CE Industry Performance Awards

This year marked the third consecutive year of growth for the U.S. consumer technology industry, and we’re excited to celebrate a few of the companies that achieved success in this competitive landscape over the past year.

Today, The NPD Group revealed the winners of its fourth annual Consumer Electronics Industry Performance Awards at the Consumer Electronics Show in Las Vegas. Awards were given to consumer electronics brands that achieved the top increases in market share in North America[1], according to NPD’s Retail Tracking Service, and the fastest-turning brand per item in the U.S.[2], according to NPD’s Store-Level Enabled data.

This year’s awards include a focus on smartphones, with honors given to brands that achieved the fastest growth based on unit percentage increase in the U.S., Canada, and Mexico[3]. These awards are based on data from NPD’s new Mobile Phone Tracking service, which leverages advertising technology to track devices as they interact with the North American ad-server network. This along with NPD’s unique data assets provides insight into market sizing, attribute tracking and regional trends.

“This year marked the third consecutive year of growth for the U.S. consumer technology industry, and we’re excited to celebrate a few of the companies that achieved success in this competitive landscape over the past year,” said Ian Hamilton, President, Technology Sector, The NPD Group. “Congratulations to all award winners – and best of luck in 2020.”

[1]Based on dollar market share increase across North America (U.S., Canada, and Mexico)

[2]Based on weighted dollar velocity per item for brands with distribution in retailers that represent at least 10% of NPD tracked CE sales in the U.S.

[3]Based on the top unit percentage change. Minimum based off of a benchmark across countries equivalent to 50K units in the U.S.

About The NPD Group, Inc.

NPD offers data, industry expertise, and prescriptive analytics to help our clients grow their businesses in a changing world. Over 2,000 companies worldwide rely on us to help them measure, predict, and improve performance across all channels, including brick-and-mortar and e-commerce. We have offices in 29 cities worldwide, with operations spanning the Americas, Europe, and APAC. Practice areas include apparel, appliances, automotive, beauty, books, B2B technology, consumer technology, e-commerce, fashion accessories, food consumption, foodservice, footwear, home, juvenile products, media entertainment, mobile, office supplies, retail, sports, toys, travel retail, video games, and watches. For more information, visit npd.com. Follow us on Twitter: @npdgroup and @npdtech.

Share article on social media or email:



RealStreet Hires Rob Sizemore as a Business Development Manager


News Image

Mr. Sizemore is a skilled and accomplished sales professional. We believe he will have a great impact on the success of the branch and play a large role in the continued growth of the company.

RealStreet, a leading national employment and recruiting firm for the architecture, engineering and construction (AEC) communities throughout the United States, is thrilled to announce the addition of Rob Sizemore as a Business Development Manager in the company’s Aberdeen, MD office.

“We are excited for this exceptional addition to the RealStreet team,” said RealStreet President, Judith McGovern. McGovern elaborated stating that, “Mr. Sizemore is a skilled and accomplished sales professional. We believe he will have a great impact on the success of the branch and play a large role in the continued growth of the company.”

Rob comes to RealStreet with over 25 years of experience. During this time, he held sales and management roles in the modular storage as well as the AEC industries. His previous business development, customer relationship management and leadership experience will allow him to cultivate lasting partnerships and enable his ongoing success.

For more information about Rob Sizemore, please visit our Team Bios page.

Follow RealStreet on Social Media:

About RealStreet

RealStreet matches professionals with career opportunities in the federal, architecture, engineering and construction communities. From commercial and private ventures to government initiatives, our professionals provide solutions for clients throughout the continental U.S. Our exclusive industry focus, firsthand construction experience, and professional recruiting expertise lay a solid foundation for the success of clients and candidates alike. RealStreet provides clients with flexible options, such as employee leasing, temp-to-hire or direct hire employment solutions. Our ‘True-Match’ recruiting process helps clients meet their goals by providing quick access to executive-level professionals, which enables them to reduce costs and meet critical deadlines. Ensure the success of your next initiative with RealStreet! For more information regarding RealStreet, visit http://www.realstreet.com.

Share article on social media or email:

FDAnews Announces — China’s NMPA (CFDA):Latest Regulatory Updates with QMS-PMS Focus Webinar January 21, 2020


WCG FDANews

WCG FDANews

China’s NMPA (CFDA):

Latest Regulatory Updates with QMS-PMS Focus

An FDAnews Webinar

Tuesday, Jan. 21, 2020, 11:00 a.m.-12:30 p.m. EST

https://www.fdanews.com/chinanpma

China is the second-largest medical device and in vitro diagnostic (IVD) industry market globally. It is the only market with a 20 percent annual growth rate year after year.

Stay up to speed on the hundreds of new regulations introduced by China’s National Medical Products Administration (NMPA) — formally known as the China Food and Drug Administration.

What are the strategic factors to consider during the reform before submission?

Join us on Jan. 21 and get up to speed on the regulatory reform in China that impacts the medical device and IVD industry.

During the webinar, attendees will:


  • Determine how to leverage a legal agent in China to increase compliance by understanding their roles and responsibilities
  • Discover how to assess and determine the new piloted MAH system by understanding its MAH qualification requirements and responsibilities
  • Familiarize oneself with how to leverage overseas QMS for China operations by understanding China GMP regulations and Chinese culture differences
  • Find out how to comply with required adverse events (AE) and serious adverse events (SAE) reports, including how to differentiate between AE and SAE and when to report

Join us for clarity on China’s regulatory reforms impacting the medical device and IVD industry.

Interested in registering multiple sites?

Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally

to learn about our special multisite discount.

Webinar Details:

China’s NMPA (CFDA):

Latest Regulatory Updates with QMS-PMS Focus

An FDAnews Webinar

Tuesday, Jan. 21, 2020, 11:00 a.m.-12:30 p.m. EST

https://www.fdanews.com/chinanpma

Tuition:

$287 per site

Easy Ways to Register:

Online: https://www.fdanews.com/chinanpma

By phone: 888-838-5578 or 703-538-7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations.

Share article on social media or email:

MMJ International Holdings Overcomes Big Federal Deterrents In It’s Marijuana Drug Development Strategy


News Image

MMJ DEA MEETING

Duane Boise stated, “The FDA has made an award for ″Orphan Drug Designation″ for MMJ’s THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease”.

MMJ International Holdings, the premier medical cannabis research company, recently announced that the FDA has made an award for ″Orphan Drug Designation″ for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease. The drug, MMJ-002 is one of MMJ’s lead drugs and the company is confident that it will bring much needed relief to patients suffering from the debilitating effects of Huntington’s Disease.

Since 2015, MMJ has been advancing the science of medical marijuana federally legal through development of patient clinical trials and research. This latest award of Orphan Drug Designation is in keeping with MMJ’s mission to do everything possible to improve the lives of patients.

Francis Collins, director of the National Institutes of Health (NIH), recently interviewed on CSPAN, was discussing some of his concerns on marijuana and the lack of research. He mentioned that products must come from a single source and be consistent in clinical trials. Collins stated “When it comes to Cannabis the United States is at an interesting place. In order to use federal funds to research the plant and its compounds, the products must come from a single source: a government-authorized farm at the University of Mississippi that cultivates marijuana.

However, MMJ International Holdings has accomplished a major milestone with the DEA’s recent approval of MMJ International Holdings, THC and CBD international shipment to the United States for Multiple Sclerosis, Huntington’s Disease Drug Development. MMJ has established a leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.

Director Francis Collins also stated, “It’s going to be very hard to interpret data about smoked marijuana when the actual nature of the product is vastly different depending on where you got it with respect to properties like THC and CBD content. We’d really like to have studies where you’re studying those compounds in pure form so you can see what they’re doing,” he said. “But again because of various limitations of Schedule I limits, we are not able to do as much as we would like.”

MMJ International Holdings, having overcome this logistical hurdle, has provided for the production of proprietary cannabis-based gel capsules to help treat those with Huntington’s Disease or Multiple Sclerosis. A new product mix of THC (tetrahydrocannabinol) and CBD (cannabidiol) will comply with the harsh guidelines set by the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA). With MMJ following these guidelines set by the FDA and DEA we can ensure our product is consistent and meets all standards to make it an effective drug for patients who suffer from these debilitating diseases.

MMJ International Holdings already has several academic institutions preparing to study cannabis in Multiple Sclerosis and Huntington’s disease. “MMJ clinical trials will provide the necessary data to prove that cannabis can treat essential tremors, a neurological disorder that causes involuntary shaking.” Tim Moynahan the company chairman further stated that, “Ultimately, there’s so much interest in THC and CBD as a treatment modality, so MMJ will be providing the clinical research data necessary to prove patient dosing, safety, and efficacy.”

“Approval by DEA and FDA trials is another “big deterrent” to research is the extensive series of hurdles that scientists must overcome to receive approval to study marijuana”, Collins said. Researchers must be cleared by the Drug Enforcement Administration (DEA) and also submit an investigational new drug application to the Food and Drug Administration in order to conduct cannabis-involved clinical studies on humans.

“MMJ International Holdings has submitted to the FDA an Investigational New Drug application” stated Duane Boise, CEO. “We are pleased with the FDA ‘s cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from MS and Huntington’s disease.”

“As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”

In conclusion, MMJ International Holdings has established a leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise. MMJ is successfully developing several prescription medications derived from the cannabis plant for the treatment of spasticity and chorea due to multiple sclerosis and Huntington’s disease.

The company has a pipeline of additional clinical stage cannabinoid and other natural botanical product candidates for both orphan and non-orphan indications with a specific focus on neurological conditions.

Share article on social media or email:

Envision Dallas Unveiled as New Name of Dallas Lighthouse for the Blind


Logo

Dallas Lighthouse for the Blind has been renamed Envision Dallas and officially become an entity of Wichita, Kan.-based Envision, Inc.

We are proud to expand our geographic footprint and mission into the Dallas area to meet a growing need for low vision rehabilitation, programs, services and employment.

Envision today announced Envision Dallas as the new name for Dallas Lighthouse for the Blind. The rebranding formalizes a relationship initiated in 2018, when the Wichita, Kansas-based Envision added Dallas Lighthouse for the Blind to its growing family. With locations in 11 states, Envision is one of the country’s largest employers of people with visual impairments. Envision’s mission is to improve the quality of life and provide inspiration and opportunity for people who are blind or visually impaired through employment, outreach, rehabilitation, education and research.

“We are proud to expand our geographic footprint and mission into the Dallas area to meet a growing need for low vision rehabilitation, programs, services and employment,” said Michael Monteferrante, president and CEO of Envision. “We look forward to the evolution of Envision Dallas into an even more robust organization led by Executive Director David Stupay and to identifying additional opportunities to help people with vision loss nationwide.”

Stupay, a veteran leader of multiple agencies in several states that help children and adults with developmental disabilities, was named as the new executive director on December 12.

Established in 1931, Envision Dallas currently serves 150,000 people in 11 North Texas counties who are blind or low vision. Since joining the Envision family, Envision Dallas has served an increasing number of people with vision loss through new initiatives and strategic leadership. In October, Envision Dallas announced it will become the new home of the American Foundation for the Blind Center on Vision Loss and Esther’s Place, a specially designed model apartment that helps individuals who are blind or low vision learn to live more independently.

About Envision: Envision promotes advocacy and independence for those who are blind or low vision. Founded in 1933, Envision is one of the largest employers of individuals with vision loss in the nation. Headquartered in Wichita, Kan., Envision’s mission is to improve the quality of life and provide inspiration and opportunity for people who are blind or visually impaired through employment, outreach, rehabilitation, education and research. For more information, visit http://www.envisionus.com.

Share article on social media or email:

Catalent Completes Purchase of Biologics Fill-Finish and Oral Solid Dose Facility in Anagni, Italy


The Anagni facility supplements our European commercial supply capabilities and will integrate well with our existing global early development and clinical supply sites to smooth the transition from development to commercial supply.

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced the completion of the purchase of Bristol-Myers Squibb’s biologics, sterile, and oral solid dose product manufacturing and packaging facility in Anagni, Italy.

The 28,000 square-meter (305,000 square-feet) facility has a demonstrated track record in technical transfers and successful commercial product launches. It offers extensive capabilities in aseptic liquid and powder filling for biologics and sterile products across multiple vial sizes, and comprehensive primary and secondary packaging solutions, including serialization, to support product launches for oral solids, sterile, and biologics products. Catalent has also announced that it plans to make further investments in the site’s growth.

“The Anagni facility supplements our European commercial supply capabilities and will integrate well with our existing global early development and clinical supply sites to smooth the transition from development to commercial supply,” commented Alessandro Maselli, Catalent’s President and Chief Operating Officer. “Anagni provides our European customers with great biologics and oral dose capabilities that can help us reduce time-to-market, simplify tech transfers, and minimize program risk.”

As part of the acquisition, Catalent will continue to manufacture the existing Bristol-Myers Squibb product portfolio currently produced at the site.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email: